Area:
Immunology, Molecular Biology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Britte C. Beaudette-Zlatanova is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2009 — 2010 |
Beaudette-Zlatanova, Britte C |
F32Activity Code Description: To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Supplementation of Cord Blood Transplants With Limphoid Progenitors @ Loyola University Chicago
DESCRIPTION (provided by applicant): Cord blood (CB) is a source of hematopoietic stem cells (HSC) for patients with hematological diseases and disorders that do not have an HLA matched bone marrow donor. Two impediments to the successful use of CB transplantation are the low number of HSC in CB and the high rate of infection due to delayed establishment of immunocompetence. It is hypothesized that supplementing CB transplants with ex vivo- expanded lymphoid progenitors will increase transplant cell number and provide a source of rapidly engrafting antigen-responsive cells while CB HSC mature in the bone marrow. Recently, in vitro culture conditions for expanding T cell progenitors from CB HSC on a human non-tumorogenic thymic epithelial cell line (TEC) have been discovered. The first aim of this project is to expand large numbers of B cell progenitors from CB HSC which, in combination with T cell progenitors, should provide complete adaptive immune protection for transplant patients. In addition to adapting TEC cultures to support B cell development, we will explore whether adherent cells of the omentum, a site of fetal B lymphopoiesis, can provide an appropriate microenvironment for the expansion and differentiation of CB HSC. The second aim of this project is to test whether in vitro generated lymphoid progenitors engraft rapidly and are functional. The capacity of the ex vivo-generated lymphoid progenitors to rapidly engraft will be assessed by injecting irradiated, immunodeficient NOD/SCID/IL2Rgamma null mice with lymphoid cells from either cultured CB or uncultured CB. Lymphocyte function in reconstituted mice challenged with a T-dependent and T- independent antigen will be assessed by: 1) measuring antibody production by ELISA and 2) performing CDR3 spectratype analysis to determine whether or not the response to antigen is polyclonal. PUBLIC HEALTH RELEVANCE: Cord blood transplantation is a therapy for immunodeficiency disorders, congenital anemia, leukemia, and other hematopoietic diseases and disorders. The aims of this project support the long-term goal of improving the success of cord blood transplantation by increasing the number of transplanted cells and rapidly establishing immunocompetence in transplant patients. We anticipate that achievement of this goal will reduce mortality due to post-transplant infection and make cord blood transplants available to patients of all ages, ethnicities, and both genders.
|
0.936 |